Conditions: Chronic Kidney Disease End-Stage Renal Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 712
Healthy volunteers: no

Brief summary:
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania.

The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.

Detailed description:
The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.

Arms:
arm 1: Somatropin once daily from week 0 to end of trial arm 2: Placebo once daily to end of trial

Interventions: intervention 1: somatropin intervention 2: placebo
Intervention descriptions: intervention 1: 20 mcg/kg/day, injected s.c. (under the skin) intervention 2: Placebo injected s.c (under the skin)

Protocol document: